Vaccine-preventable diseases in long-term expatriates

Journal of Travel Medicine

Volumn 12, Issue SUPPL. 1, 2005, Pages

  Dijkstra, Jan A ^a   Chappuis, François ^a   Loutan, Louis ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; ANTIBIOTIC AGENT; BCG VACCINE; CHICKENPOX VACCINE; CHLORAMPHENICOL; CHOLERA VACCINE; CIPROFLOXACIN; COTRIMOXAZOLE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HEPATITIS A VACCINE; HEPATITIS B VACCINE; INFLUENZA VACCINE; JAPANESE ENCEPHALITIS VACCINE; MEASLES MUMPS RUBELLA VACCINE; MENINGOCOCCUS VACCINE; PNEUMOCOCCUS VACCINE; POLIOMYELITIS VACCINE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RABIES IMMUNOGLOBULIN; RABIES VACCINE; RIFAMPICIN; TICK BORNE ENCEPHALITIS VACCINE; TYPHOID VACCINE; YELLOW FEVER VACCINE;

ADULT; ANGIONEUROTIC EDEMA; ANTHRAX; BACTERIAL INFECTION; BCG VACCINATION; BIOLOGICAL WARFARE; CHICKENPOX; CHILD; CHILD HEALTH CARE; CHOLERA; DIPHTHERIA; DRUG INDUCED DISEASE; ENDEMIC DISEASE; EPIDEMIC; EPIDEMIC ENCEPHALITIS; EXPATRIATE; FAMILY; FEMALE; HAEMOPHILUS INFLUENZAE TYPE B; HEALTH PROMOTION; HEPATITIS A; HEPATITIS B; HUMAN; INFANT; INFECTION; INFLUENZA; MALE; MEASLES; MENINGOCOCCOSIS; MUMPS; OCCUPATION; PERTUSSIS; POLIOMYELITIS; PRACTICE GUIDELINE; PREGNANCY; RABIES; RELIGIOUS GROUP; REVIEW; RISK FACTOR; RUBELLA; SMALLPOX; TETANUS; THYMUS DISEASE; TICK BORNE ENCEPHALITIS; TRAVEL; TUBERCULOSIS; TYPHOID FEVER; URTICARIA; VACCINATION; VIRUS INFECTION; YELLOW FEVER; YELLOW FEVER VACCINE ASSOCIATED VISCEROTROPIC DISEASE;

EID: 17844390133     PISSN: 11951982     EISSN: None     Source Type: Journal    
DOI: 10.2310/7060.2005.12057     Document Type: Review

References (76)

1. Lange WR, Frankenfield DL, Frame JD. Morbidity among refugee relief workers. J Travel Med 1994; 1:111-112.
2. Leutscher PD, Bagley SW. Health related challenges in United States Peace Corps volunteers serving for two years in Madagascar. J Travel Med 2003; 10:263-267.
3. Sharp TW, De Freitas RF, Thornton SA, et al. Illness in journalists and relief workers involved in international humanitarian assistance efforts in Somalia, 1992-1993. J Travel Med 1995; 2:70-76.
4. Hargarten SW, Baker S. Fatalities in the Peace Corps, a retrospective study: 1962 to 1983. JAMA 1985; 254: 1326-1329.
5. Frame JD, Lange R, Frankenfield DL. Mortality trends of American missionaries in Africa, 1945-1985. Am J Trop Med Hyg 1992; 46:686-690.
6. Sheik M, Gutierrez MI, Bolton P, et al. Deaths among humanitarian workers. BMJ 2000; 321:166-168.
7. Peytremann I, Badureaux M, O'Donovan S, Loutan L. Medical evacuations and fatalities of United Nations High Commissioner for refugee field employees. J Travel Med 2001; 8:117-121.
8. Seet B, Burnham G. Fatality trends in United Nations peace-keeping operations, 1948-1998. JAMA 2000; 284:598-603.
9. Bunn W. Vaccine and international health programs for employees travelling and living abroad. J Travel Med 2001; 8(Suppl 1):S20-S23.
10. Monath TP, Cetron MS. Prevention of yellow fever in persons travelling to the tropics. Clin Infect Dis 2002; 34: 1369-1378.
11. World Health Organization. Yellow fever, 1998-1999. Wkly Epidemiol Rec 2000; 75:322-327.
12. Barwick R, for the Yellow Fever Vaccine Safety working group. History of thymoma and yellow fever vaccination. Lancet 2004; 364:936.
13. Steffen R. Risk of hepatitis A in travellers. Vaccine 1992; 10(Suppl 1):S69-S72.
14. Larouzé B, Gaudebout C, Mercier E, et al. Infection with hepatitis A and B viruses in French volunteers working in tropical Africa. Am J Epidemiol 1987; 126:31-37.
15. Lange WR, Frame JD. High incidence of viral hepatitis among American missionaries in Africa. Am J Trop Med Hyg 1990; 43:527-533.
16. Poland GA, Axelsen PH, Felz MW. Hepatitis A and B infections among expatriates in Papua New Guinea: a missed opportunity for immunization. J Travel Med 1996; 3:209-213.
17. Hoke CH, Binn LN, Egan JE, et al. Hepatitis A in the US Army: epidemiology and vaccine development. Vaccine 1992; 10(Suppl 1):S75-S79.
18. Hesla PE. Hepatitis A in Norwegian troops. Vaccine 1992; 10:S80-S81.
19. Van Damme P, Banatvala J, Fay O, et al. Hepatitis A booster vaccination: is there a need? Lancet 2003; 362: 1065-1071.
20. Steffen R. Hepatitis A and hepatitis B: risks compared with other vaccine preventable diseases and immunisation recommendations. Vaccine 1993; 11:518-520.
21. Cobelens FGJ, van Schothorst HJ, Wertheim-van Dillen PME, et al. Epidemiology of hepatitis B infection among expatriates in Nigeria. Clin Infect Dis 2004; 38:370-376.
22. Bonneux L, van der Stuyft P, Taelman H, et al. Risk factors for HIV infections among European expatriates in Africa. BMJ 1988; 297:581-584.
23. Houweling H, Coutinho RA. Risk of HIV infection among Dutch expatriates in sub-Saharan Africa. Int J STD AIDS 1991; 2:252-257.
24. Goettsch W, de Graaf R, Dorigo-Zetsma JW, et al. Broader vaccination of expatriates against HBV infection: do we reach those at higher risk? Int J Epidemiol 1999; 28: 1161-1166.
25. Steffen R. Immunization against hepatitis A and hepatitis B infections. J Travel Med 2001;8(Suppl 1):S9-S16.
26. Edelman R, Levine MM. Summary of an international workshop on typhoid fever. Rev Infect Dis 1986; 8:329-349.
27. Mermin JH, Townes JM, Gerber M, et al. Typhoid fever in the United States, 1985-1994. Changing risks of international travel and increasing antimicrobial resistance. Arch Intern Med 1998; 158:633-638.
28. Tarr PE, Kuppens L, Jones TC, et al. Considerations regarding mass vaccination against typhoid fever as an adjunct to sanitation and public health measures: potential use in an epidemic in Tajikistan. Am J Trop Med Hyg 1999; 61:163-170.
29. Levine MM, Ferreccio C, Abrego P, et al. Duration of efficacy of Ty21a, attenuated Salmonella typhi live oral vaccine. Vaccine 1999; 17(Suppl 2):S22-S27.
30. Klugman KP, Koornhof HJ, Robbins JB, Le Cam NN. Immunogenicity, efficacy and serological correlate of protection of Salmonella typhi Vi capsular polysaccharide vaccine three years after immunization. Vaccine 1996; 14:435-438.
31. Engels EA, Falagas ME, Lau J, Bennish ML. Typhoid fever vaccines: a meta-analysis of studies on efficacy and toxicity. BMJ 1998; 316:110-116.
32. Ferreccio C, Levine MM, Rodriquez H, Contreras R. Comparative efficacy of two, three, four doses of Ty21a live oral typhoid vaccine in enteric-coated capsules: a field trial in an endemic area. J Infect Dis 1999; 159:766-769.
33. Memish ZA. Meningococcal disease and travel. Clin Infect Dis 2002; 34:84-90.
34. World Health Organization. Detecting meningococcal meningitis epidemics in highly-endemic African countries. Wkly Epidemiol Rec 2000; 38:306-309.
35. Pollard AJ, Shlim DR. Epidemic meningococcal disease and travel. J Travel Med 2002; 9:29-33.
36. Koch S, Steffen R. Meningococcal disease in travellers: vaccination recommendations. J Travel Med 1994; 1:4-7.
37. Wilder-Smith A, Paton NI. Crossover vaccination with quadrivalent meningococcal vaccine (against A/C/Y/W-135) following recent application of bivalent meningococcal vaccine (against A/C): assessment of safety and side effect profile. J Travel Med 2002; 9:20-23.
38. Plotkin SA. Rabies. Clin Infect Dis 2000; 30:4-12.
39. Wilde H, Briggs DJ, Meslin FX, et al. Rabies update for travel medicine advisors. Clin Infect Dis 2003; 37:96-100.
40. Warrell MJ, Warrell DA. Rabies and other lyssavirus diseases. Lancet 2004; 363:959-969.
41. Hatz CF, Bidaux JM, Eichenberger K, et al. Circumstances and management of 72 animal bites among long-term residents in the tropics. Vaccine 1995; 13:811-815.
42. Bjorvatn B, Gundersen SG. Rabies exposure among Norwegian missionaries working abroad. Scand J Infect Dis 1980; 12:257-264.
43. Bernard KW, Fishbein DB. Pre-exposure rabies prophylaxis for travellers: are the benefits worth the cost? Vaccine 1991; 9:833-836.
44. Pandey P, Shlim D, Cave W, et al. Risk of possible exposure to rabies among tourists and foreign residents in Nepal. J Travel Med 2002; 9:127-131.
45. Phanuphak P, Ubolyam S, Sirivichyakul S. Should travellers in rabies endemic areas receive pre-exposure rabies immunisation? Ann Med Interne Paris 1994; 145:409-411.
46. Strady A, Lang J, Lienard, et al. Antibody persistence following pre-exposure regimens of cell culture rabies vaccine: 10-year follow-up and proposal for new booster policy. J Infect Dis 1998; 177:1290-1295.
47. Plotkin S, Rupprecht C, Koprowski H. Rabies vaccine. In: Plotkin S, Orenstein W, eds. Vaccines. Philadelphia, PA: WB Saunders, 2004:1011-1038.
48. Centers for Disease Control and Prevention. Inactivated Japanese encephalitis virus vaccine: recommendations of the advisory committee on immunization practises (ACIP). MMWR 1993; 42(RR-1):1-15.
49. Shlim DR, Solomon T. Japanese encephalitis vaccine for travellers: exploring the limits of risk. Clin Infect Dis 2002; 35:183-188.
50. Halstead SB, Grosz CR. Subclinical Japanese encephalitis infection of Americans with limited residence in Korea. Am J Hyg 1962; 75:190-201.
51. Hoke CH, Nisalak A, Sangawhipa N, et al. Protection against Japanese encephalitis by inactivated vaccines. N Engl J Med 1989; 319:609-614.
52. Plesner A, Ronne T. Allergic mucocutaneous reactions to Japanese encephalitis vaccine. Vaccine 1997; 15:1239-1243.
53. Dumpis U, Crook D, Oksi J. Tick-borne encephalitis. Clin Infect Dis 1999; 28:882-890.
54. World Health Organization. Tick-borne encephalitis. Wkly Epidemiol Rec 1995; 70:120-122.
55. McNeil JG,Lednar WM, Stansfield SK, et al. Central European tick-borne encephalitis assessment of risk for persons in the Armed Forces and vacationers. J Infect Dis 1985; 152:650-651.
56. Kunz C, Hofmann H, Dippe H. Die FSME-Imphung, eine mässnahme der Vorsorgemedizin mit höher akzeptanz in Asterreich. Wien Med Wschr 1991; 141:273-276.
57. Demicheli V, Graves P, Pratt M, Jefferson T. Vaccines for preventing tick-borne encephalitis (Cochrane review). In: The Cochrane Library, Issue 1. Chichester: Wiley, 2004.
58. Ryan ET, Calderwood SB. Cholera vaccines. Clin Infect Dis 2000; 31:561-565.
59. Taylor DN, Rizzo J, Meza R, et al. Cholera among Americans living in Peru. Clin Infect Dis 1996; 22:1108-1130.
60. Clemens JD, Sack DA, Harris JR, et al. Field trial of oral cholera vaccines in Bangladesh. Lancet 1986; 2:124-127.
61. Levine MM, Kaper JB. Live oral vaccines against cholera: an update. Vaccine 1993; 11:207-212.
62. World Health Organization. Cholera vaccines: a new public health tool? Report WHO/CDC/CPE/ZFK/2004.5. Geneva: WHO, 2004.
63. Rieder HL. Risk of travel-associated tuberculosis. Clin Infect Dis 2001; 33:1393-1396.
64. Cobelens FGJ, van Deutekom H, Draayer-Jansen IWE, et al. Risk of infection with Mycobacterium tuberculosis in travellers to areas of high tuberculosis endemicity. Lancet 2000; 356:461-465.
65. Bonifacio N, Saito M, Gilman RH, et al. High risk for tuberculosis in hospital physicians. Emerg Infect Dis 2002; 8:747-748.
66. Kortepeter MG, Krauss MR. Tuberculosis infection after humanitarian assistance, Guantanamo Bay, 1995. Mil Med 2001; 166:116-120.
67. Cobelens FGJ, Draayer-Jansen EWE, Schepp-Beelen JC HM, et al. Limited tuberculin screening participation amongst travellers to countries with high tuberculosis incidence; reason to consider BCG vaccination for some travellers. Ned Tijdschr Geneesk 2003; 147:561-565. (In Dutch.)
68. Brewer TF. Preventing tuberculosis with BCG: a meta-analysis of the literature. Clin Infect Dis 2000;31(Suppl 3):S64-S67.
69. World Health Organization. BCG vaccine. WHO position paper. Wkly Epidemiol Rec 2004; 79:27-38.
70. Mutsch M, Tavernini M, Marx A, et al. Influenza virus infection in travelers to tropical and subtropical countries. Clin Infect Dis 2005; in press.
71. El Bashir H, Haworth E, Zambon M, et al. Influenza among UK pilgrims to Hajj, 2003. CDC Emerg Infect Dis 2004; 10:1882-1883.
72. Leder K, Sundararajan V, Weld L, et al. Respiratory tract infections in travellers: a review of the GeoSentinel surveillance network. Clin Infect Dis 2003; 36:399-406.
73. Centers for Disease Control and Prevention. Prevention and control of influenza: recommendations of the advisory committee on immunization practices (ACIP). MMWR 2000; 49(RR-3):6-7.
74. Centers for Disease Control and Prevention. YF vaccine. Recommendations of the Immunization Practices Advisory Committee (ACIP). MMWR 1990; 39(RP6):1-6.
75. MacLennan J, Obaro S, Deek J, et al. Immune response to revaccination with meningococcal A and C polysaccharides in Gambian children following repeated immunisation during early childhood. Vaccine 1999; 17:3086-3093.
76. World Health Organization. International travel and health. Geneva: WHO, 2003: 113-114.